Siris Medical Inc., a member of North Shore InnoVentures, announced that it has raised $4.0 million in Series A1 financing. Founded with the vision of leveraging data analytics to improve treatment delivery and outcomes for patients undergoing radiation therapy for cancer treatment, Siris will use the funds to expand the commercialization of its QuickMatch™ software.
Siris Medical develops and commercializes solutions at the interface of engineering and medicine, focusing on clinical needs in cancer diagnosis and therapy.
Since co-founding Siris Medical in 2013, Colin Carpenter has served as its CEO, commercially introducing the first decision-support system for radiation oncology using artificial intelligence. This platform helps determine the best treatment for patients by learning from past success. Siris has been recognized for innovation, winning an award at the ESTRO 2017 conference and an Innovator award from the UCSF/Rosenman Institute.
Prior to Siris, Colin trained in the Department of Radiation Oncology at Stanford, where he founded a company to commercialize a brachytherapy product line for GI cancer, sold by Varian Medical Systems (VMS). At Dartmouth, Colin led the early clinical validation of a breast cancer imaging device to reduce false positive results. This work resulted in a US Patent, a DoD Breast Cancer Fellowship grant, and numerous publications.
Colin is a contributor to over 100 technical and medical publications and is an alumnus of Stanford Biodesign. He received a BA in Physics from CU-Boulder and a PhD in Engineering Sciences from Dartmouth.
Read the full press release on Business Wire.